In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

Celebrating 10 years as the definitive platform for the NK community, the flagship Innate Killer Summit will unite ...

In the era of digital health transformation, generative AI (GenAI) has emerged as a breakthrough technology in ...

Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the ...

Medicare coverage would reduce out-of-pocket costs for AOMs – which can currently be as high as $1,000 a month - by as much ...

Medigene has said it will cut 40% of its workforce and delay the start of clinical trials of its lead asset as it re-jigs its ...

Returning for its 15th anniversary year, World ADC London is the leading European conference uniting over 1000 ADC ...

The Swiss pharma group has agreed a $9 per share deal to acquire Poseida, valuing the company at around $1 billion, with another $500 million potentially payable to shareholders in a contingent value ...

In March, Winrevair became the first FDA-approved therapy for PAH that addresses the underlying mechanism behind the disease, ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...